Last reviewed · How we verify

LTOT 15h/day

Skane University Hospital · FDA-approved active Small molecule

LTOT 15h/day refers to long-term oxygen therapy administered for 15 hours per day, which increases blood oxygen saturation in patients with chronic hypoxemia.

LTOT 15h/day refers to long-term oxygen therapy administered for 15 hours per day, which increases blood oxygen saturation in patients with chronic hypoxemia. Used for Chronic hypoxemia secondary to chronic obstructive pulmonary disease (COPD), Interstitial lung disease with chronic hypoxemia, Other chronic respiratory conditions with resting or exertional hypoxemia.

At a glance

Generic nameLTOT 15h/day
Also known asLong-term oxygen therapy prescribed for 15 h/day
SponsorSkane University Hospital
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Long-term oxygen therapy (LTOT) is a supportive treatment that delivers supplemental oxygen to patients with chronic lung diseases or conditions causing persistent low blood oxygen levels. By increasing inspired oxygen concentration, LTOT improves arterial oxygen saturation, reduces pulmonary vasoconstriction, and decreases the workload on the heart and respiratory system. The 15-hour daily regimen is a standard dosing schedule used to manage chronic hypoxemia while allowing periods without supplemental oxygen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: